Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Steven Kelly, President and CEO, will represent the company at the conference on Tuesday, February 11 at 4:40 pm ET.
The presentation will be accessible via audio webcast through the Company's Investor Events section on their Investor Relations webpage, with -time archive availability following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CARM gained 15.95%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.
Investors:
Shveta Dighe
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367990.html
SOURCE Carisma Therapeutics Inc.